New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell ...

America's Clean Energy Company™, announced today important new uranium discoveries have been made in areas in or near ...

Johnson & Johnson ( NYSE: JNJ) Q3 2025 Earnings Call October 14, 2025 8:30 AM EDT Good morning, and welcome to Johnson & Johnson's Third Quarter 2025 Earnings Conference Call. [Operator Instructions] ...

Passive Electromagnetic Shielding Solution Addresses Growing Contactless Payment Security Concerns; Security Experts Report Increased Digital Pickpocketing in High-Traffic Urban Areas ...